Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

Delayed Quote. Delayed  - 07/28 04:24:50 pm
21050 ILa   +0.62%
07/28 ALLERGAN : Teva receives US clearance for Actavis acquisition
07/28 TEVA PHARMACEUT : US FTC approves Tevas $40.5bn deal for Allergans g..
07/28 TEVA PHARMACEUT : Receives Clearance from the U.S. Federal Trade Com..
News SummaryMost relevantAll newsSector news 

Teva Asks FDA Not to Approve New MS Drugs Till Advisers Evaluate Safety

share with twitter share with LinkedIn share with facebook
share via e-mail
01/09/2013 | 09:09pm CEST
   By Peter Loftus 

Teva Pharmaceutical Industries Ltd. (>> Teva Pharmaceutical Industries Ltd (ADR)), which sells the blockbuster multiple-sclerosis drug Copaxone, has asked the U.S. Food and Drug Administration not to approve any new MS drugs until their safety risks have been evaluated by outside advisers.

Teva's petition is aimed at Biogen Idec Inc. (>> Biogen Idec Inc.), which expects an FDA decision by late March on Biogen's application to market a new MS treatment, known as BG-12, an orally administered pill that analysts expect will be a formidable competitor to the injected Copaxone.

In a Dec. 31 citizen petition to the FDA, Teva asked the agency not to approve any new MS drugs until the agency refers them to an advisory committee for evaluation. Advisory committees sometimes review new drug applications to provide guidance to the agency.

Teva said it was important for the agency to hear outside advisers' evaluations of any safety risks, in light of risks that have emerged after MS treatments were approved in recent years, including Biogen's own Tysabri MS treatment. Tysabri was removed from the market soon after its 2004 introduction after some recipients experienced a serious brain infection, and reintroduced in 2006 with a patient-monitoring plan.

Teva said in its petition that BG-12 "may be associated with other serious safety risks" including the potential risk for kidney-related problems.

Teva cited a publicly accessible website containing animal toxicology data suggesting that kidney changes were seen in animals after they received BG-12's active ingredient, dimethyl fumarate, in studies. The website stated that the relevance of these findings to humans isn't known, according to the Teva petition.

Biogen spokeswoman Kate Niazi-Sai said the company is confident in the clinical data supporting BG-12's safety and efficacy, and the regulatory review appears to be on track.

Results of a late-stage clinical trial of BG-12 published last year in the New England Journal of Medicine showed the incidence of kidney-related adverse events was similar between those receiving BG-12 and those on a placebo. There were no cases of kidney failure classified by researchers as serious adverse events, according to the article.

RBC Capital Markets analyst Shibani Malhotra, who reported the Teva citizen petition in a research note earlier Wednesday, said it may not pose a big obstacle for BG-12's approval because a similar drug has been available as a psoriasis treatment in Europe, and serious safety issues haven't emerged.

RBC analyst Michael Yee said he still expects the FDA to approve BG-12 by the targeted action date in late March.

On Monday at the J.P. Morgan Healthcare conference in San Francisco, Biogen Chief Executive George Scangos defended the experimental MS pill. He acknowledged there has been some chatter about BG-12 safety, but chalked this up to competitors marketing against the product.

"We're very confident in the safety," he said. "I kind of take it as a compliment that the competition is worried about BG-12."

Teva spokeswoman Denise Bradley said the petition was intended to bring to light important points "to protect the safety of patients." Teva wants to ensure "that appropriate safeguards are implemented to maintain an acceptable risk-benefit profile" for any new MS drug, she said.

FDA spokeswoman Sandy Walsh said the agency will review the petition.

--Jon Kamp contributed to this article.

-Write to Peter Loftus at peter.loftus@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
07/28 ALLERGAN : Teva receives US clearance for Actavis acquisition
07/28 TEVA PHARMACEUTICAL : US FTC approves Tevas $40.5bn deal for Allergans generics ..
07/28 TEVA PHARMACEUTICAL : Receives Clearance from the U.S. Federal Trade Commission ..
07/28 TEVA PHARMACEUTICAL : Agrees to Divest 79 Pharma Products to Settle Actavis Gene..
07/28DJU.S. HOT STOCKS : Hot Stocks to Watch
07/28DJFacebook Rides Mobile-Ad Surge -- WSJ
07/27 Teva, Allergan win U.S. antitrust approval for generics deal
07/27DJTEVA PHARMACEUTICAL : Correction to Teva, Allergan Article
07/27 ALLERGAN : Teva expect to close $40.5B Allergan generic deal next week
07/27 TEVA PHARMACEUTICAL : to Report Second Quarter 2016 Financial Results on August ..
More news
Sector news : Pharmaceuticals - NEC
10:54aDJSANOFI : Profit Down as Diabetes Drug Sales Slip--Update
08:56aDJSanofi Profit Down as Diabetes Drug Sales Slip
07:45aDJSANOFI : Profit Down as Diabetes Drug Sales Slip
07/28DJBRISTOL MYERS SQUIBB : -Myers Results Boosted by Cancer Drugs -- Update
07/28DJU.S. HOT STOCKS : Hot Stocks to Watch
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/28 WALL STREET BREAKFAST : Crude Nears Fresh Bear Market
07/27 U.S. FTC blesses Teva purchase of Actavis Generics
07/27 BIOTECH DAILY DIGEST : Gilead's Thud, Tobira Gets A Shout-Out, Spotlight On Adva..
07/27 Teva Growth Stock
07/26 Generics Keeping The Pressure On Big Pharma
Financials ($)
Sales 2016 22 838 M
EBIT 2016 7 265 M
Net income 2016 4 717 M
Debt 2016 25 666 M
Yield 2016 2,29%
P/E ratio 2016 12,61
P/E ratio 2017 10,41
EV / Sales 2016 3,32x
EV / Sales 2017 2,82x
Capitalization 50 200 M
More Financials
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Full-screen chart
Technical analysis trends TEVA PHARMACEUTIC...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 72,1 $
Spread / Average Target 31%
Consensus details
EPS Revisions
More Estimates Revisions
Erez Vigodman President, Chief Executive Officer & Director
Yitzhak Peterburg Chairman
Carlo de Notaristefani President & CEO-Global Operations
Eyal Desheh Chief Financial Officer & Group Executive VP
Michael R. Hayden President-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON21.16%342 345
PFIZER INC.13.60%222 398
ROCHE HOLDING LTD.-9.99%215 597
NOVARTIS AG-5.30%214 061
MERCK & CO., INC.10.62%161 736
More Results